The decreased activity/expression of GLO1 has been reported in diabetes [8,24] neurodegenerative disorders [16,25], cardiovascular diseases [12,24] and cerebrovascular diseases [15,26]. This evidence concerns the gene GLO1 and diabetes mellitus.